Screener
Aquestive Therapeutics, Inc. AQST Business Segments — Manufacture and supply
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues | $13,819 | $10,003 | $28,265 | $18,723 |
| Costs and expenses: | ||||
| Manufacture and supply | 4,017 | 4,561 | 7,486 | 8,213 |
| Research and development | 3,962 | 4,105 | 8,166 | 9,466 |
| Selling, general and administrative | 14,063 | 12,705 | 25,040 | 31,777 |
| Total costs and expenses | 22,042 | 21,371 | 40,692 | 49,456 |
| Loss from operations | (8,223) | (11,368) | (12,427) | (30,733) |
| Other income/(expenses): |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s business segments — manufacture and supply?
- Aquestive Therapeutics, Inc. (AQST) reported business segments — manufacture and supply of $4.02M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s business segments — manufacture and supply changed year-over-year?
- Aquestive Therapeutics, Inc.'s business segments — manufacture and supply decreased by 11.9% year-over-year, from $4.56M to $4.02M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s business segments — manufacture and supply?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s business segments — manufacture and supply has grown at a -5.6% compound annual growth rate (CAGR), from $20.83M to $18.56M.
- What does business segments — manufacture and supply mean?
- Includes the direct costs associated with the production, manufacturing, and supply chain logistics for the segment's product portfolio. Monitoring this metric helps assess the efficiency of production processes and the impact of input costs on segment margins. It is a key component in evaluating the cost-of-goods-sold structure for the business unit.
Ask your AI about Aquestive Therapeutics, Inc.'s business segments — manufacture and supply.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude